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BCR, break point cluster geneThe chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for
the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellu-
lar Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactiva-
tion are poorly understood. Protein tyrosine phosphatases can negatively regulate Abl mediated signaling by
dephosphorylating the kinase and/or its substrates. This study investigated the ability of the intracellular T cell pro-
tein tyrosine phosphatase (TCPTP/PTPN2) to dephosphorylate and regulate the functions of BCR-Abl and c-Abl.
TCPTP is expressed as two alternately spliced isoforms— TC48 and TC45, which differ in their C-termini and local-
ize to the cytoplasm and nucleus respectively. We show that TC48 dephosphorylates BCR-Abl but not c-Abl and
inhibits its activity towards its substrate, CrkII. Y1127 and Y1294 residues whose phosphorylation corresponds
with BCR-Abl activation status were the primary sites targeted by TC48. Co-localization and immunoprecipitation
experiments showed that TC48 interacted with BCR-Abl but not with c-Abl, and BCR domain was sufﬁcient for in-
teraction. TC48 expression resulted in the stabilization of Bcr-Abl protein dependent on its phosphatase activity.
Inactivation of cellular TC48 in K562 cells by stable expression of a dominant negative catalytically inactivemutant
TC48, enhanced proliferation. TC48 expressingK562 clones showed reducedproliferation and enhanced sensitivity
to STI571 compared to control clones suggesting that TC48 can repress the growth of CML cells. This study iden-
tiﬁes a novel cellular regulator that speciﬁcally inhibits the activity of oncogenic BCR-Abl but not that of the cellular
Abl kinase.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The non-receptor tyrosine kinase c-Abl has been implicated to func-
tion in various cellular processes like cell proliferation, actin reorganiza-
tion, migration, DNA damage response and apoptosis [1]. c-Abl activity
is repressed and tightly regulated by mechanisms, many of which are
not fully understood. Unlike c-Abl, its oncogenic counterpart, the chi-
meric BCR-Abl exhibits deregulated protein tyrosine kinase activity
and is responsible for the pathogenesis of certain human leukemias,
such as chronic myelogenous leukemia (CML) [2,3].
c-Abl is amultifunctional protein containing SH3, SH2 and actin bind-
ing domains in addition to its catalytic domain. The intrinsic kinase activ-
ity of c-Abl is stringently regulated through intra- and intermolecular
interactions and phosphorylation of critical residues [4]. SH3 domain
deletion or mutation results in an increase of kinase activity [5,6]. Muta-
tions that disrupt the auto-inhibited nature of c-Abl lead to the produc-
tion of oncogenic proteins that transform a variety of cell types. The1 40 27160222; fax: +91 40
rights reserved.BCR-Abl oncogene is a result of a chrosomosomal translocation in
which the breakpoint cluster region (BCR) gene on chromosome 22
gets fused to c-Abl proto-oncogene on chromosome 9 [7]. The encoded
fusion protein has a part of the SH3 domain of c-Abl replaced by a frag-
ment of the BCR protein. Alternative chimeric proteins, p210 BCR-Abl
and p185 BCR-Abl, are produced that are characteristic of chronic mye-
logenous leukemia and acute lymphocytic leukemia (ALL), respectively.
Phosphorylation of Y245 and Y412 of c-Abl, or analogous residues
Y1127 and Y1294 of BCR-Abl correspond with activation and correlate
with proliferation and survival properties [4,5]. In contrast to c-Abl,
which localizes to varying degrees in the cytoplasm and nucleus
depending on cell type and stimuli, BCR-Abl is exclusively localized
to the cytoplasm of cells where it activates different survival path-
ways leading to cell proliferation.
The aberrant tyrosine kinase activity of BCR-Abl causes tyrosine
phosphorylation of a large number of cellular substrates and alter-
ations in the BCR-Abl activity are reﬂected in the altered substrate
phosphorylation [1]. In addition, multiple signaling events are trig-
gered leading to the activation of transcription factors involved in
cell survival pathways that can impart tumorigenic properties. Inhibi-
tion of tyrosine kinase activity of BCR-Abl by small molecule inhibi-
tors has become a paradigm for modern targeted cancer therapy [8],
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tate additional therapeutic intervention strategies [9,10].
Some protein tyrosine phosphatases like PTPN1 [11], SHP1 [12],
PTPRγ [13], and PTPRot [14] function as negative regulators by reversing
BCR-Abl-mediated tyrosinephosphorylationeither bydephosphorylating
the kinase or its substrates. PTP-PEST is recruited by cytoskeletal adaptor
protein to dephosphorylate c-Abl [15]. T-cell protein tyrosine phospha-
tase (TCPTP or PTPN2), the closest homologue of PTPN1 [16], is known
to dephosphorylate several tyrosine kinases [17–19]. TCPTP is expressed
as two alternately spliced isoforms TC48 and TC45, which differ only in
their C-termini but exhibit distinct localization and substrate speciﬁcity.
TC45 has a DNA binding ability and localizes predominantly to the nucle-
us, whereas TC48 is associated with the nuclear membrane, endoplasmic
reticulum and Golgi [20–23]. While a large number of cellular substrates
have been identiﬁed for TC45, very few TC48 substrates are known.
TCPTP is ubiquitously expressed but shows high levels of expression in
hematopoetic cells [17,24]. TCPTP deﬁcient mice show defects in the de-
velopment of the hematopoietic system and in inﬂammatory responses
[25]. A role in insulin signaling and transformation suppression has also
been shown [26,27]. Its role in other cells and tissues is yet to be
determined. TC45 has been shown to modulate signals downstream
of BCR-Abl and its levels are downregulated in Imatinib resistant
BCR-Abl positive cells [28].
In this study, we investigated the ability of TCPTP to dephosphory-
late and regulate the functions of BCR-Abl and c-Abl. Our results identify
BCR-Abl as a novel interacting partner and substrate of TC48. Ectopic
expression of TC48 repressed BCR-Abl activity and reduced prolifera-
tion of K562 cells. TC48 interacts with the BCR domain, speciﬁcally tar-
gets BCR-Abl and does not affect c-Abl kinase functions. This study
therefore describes the identiﬁcation of a protein, which can bemanip-
ulated to selectively repress BCR-Abl activity.
2. Materials and methods
2.1. Expression constructs
Plasmids for expression of full length GFP-TC48 and GFP-TC45, have
been described earlier [21,29]. The BCR-Abl expression construct was
gifted by Dr. E. Premkumar Reddy. The human c-Abl expression vector
c-Abl pSGT and the constitutively active c-Abl mutant (ΔXB — with de-
leted SH3 domain) were kindly provided by Dr. Richard Van Etten.
pSGT AblPP (P242E, P249E) construct (Abl mPP) was kindly gifted by
Dr. Superti-Furga. This construct shows a constitutive activity due to
point mutations in the SH3 binding sequence of c-Abl. Myc-BCR expres-
sion vector was constructed by inserting a PCR ampliﬁed fragment of the
total BCR domain (from BCR-Abl plasmid) and inserting it in the pcDNA
3.1 vector digested with EcoRI and XbaI. Insert was conﬁrmed by se-
quencing. Mutant TC48 and TC45 were created by substituting aspartic
acid at 182 to alanine using site-directed mutagenesis (D182A, mTC48/
mTC45). These mutants lack catalytic activity and function as dominant
negatives as well as substrate traps [29–31]. c-Abl with deletion of its
actin binding domain (ΔFABD) and therefore lacking ability to bind
F-actin, was generated by inserting a stop codon after amino acid 1119
at C-terminal of c-Abl-pSGT construct [32].
2.2. Cell lines, transfections and generation of stable clones
HEK293 and Cos-1 cell lines were grown as monolayers in a humidi-
ﬁed atmosphere of 5% CO2 at 37 °C inDulbecco'sminimumessentialme-
dium (DMEM) containing 10% FCS. K562 cells were grown in RPMI-1640
medium containing 10% FCS. Transfections of HEK293 and Cos-1 cells
were performed as described earlier [33,34]. When BCR-Abl, c-Abl and
GFP-TCPTP constructs were co-transfected with other constructs, the
amounts of DNA used were maintained by using empty vectors as con-
trols. K562 cells were transfected with GFP, GFP-TC48 or GFP-mTC48
by electroporation using a Biorad Gene Pulser at 110 V, 950 μF followedby a selection in the G418 containing medium. Stable clones obtained
after selection in 500 μg/ml were maintained in 400 μg/ml of G418 in
RPMI.
2.3. Antibodies and reagents
Antibodies for c-Abl (mouse monoclonal), Cdk-2 (rabbit polyclonal),
CrkII (rabbit polyclonal), GFP (rabbit polyclonal andmousemonoclonal),
PY20 (mouse monoclonal), Myc (rabbit polyclonal andmousemonoclo-
nal), and α-tubulin (mouse monoclonal) were purchased from Santa
Cruz Biotechnology. Phospho-c-Abl (anti-pY245, anti-pY412) and
phospho-CrkII (anti-pY221) antibodies were from Cell Signaling Tech-
nology. The mouse monoclonal G11 antibody was raised in our labora-
tory and has been described earlier [20]. STI 571 was a gift from Natco
Pharma Ltd.
2.4. Indirect immunoﬂuorescence, confocal microscopy
Indirect immunostaining of HEK293 and Cos-1 cells and microsco-
py was carried out essentially as described [29,32]. K562 cells were
plated on 0.01% poly-L-lysine (Mol. Wt.70,000–1,50,000) coated cov-
erslips for immunoﬂuorescence. Secondary antibodies used were rab-
bit or mouse IgG coupled with either Cy3 (Amersham), Alexa 488 or
Alexa 633 (Molecular Probes) ﬂuorescent dyes. Dual staining was car-
ried out by sequential incubation with the respective primary and
secondary antibodies. Colocalization was determined by observing the
staining patterns, with the Leica TCS SP5 confocal microscope (Leica
Microsystems). Serial optical sections in the Z-axis of the cell were col-
lected at 0.5 μm intervals with 63× oil immersion objective lens. Two of
the middle optical sections were projected and colocalization was de-
termined in a total thickness of 1 μm by using a Leica application suite
advanced ﬂuorescence software. Digital images were also captured
using the Leica TCS SP5 confocal microscope (Leica Microsystems) or
with a Zeiss Axioplan2 microscope. The confocal images were captured
using a 63×/1.4NAoil immersion objectives. The images fromAxioplan2
microscope were captured using a 40×/0.75 NA dry objective. Similar
parameters of image capture were used for analysis of cover-slips be-
longing to a particular experiment.
2.5. Immunoprecipitation and Western blotting
Immunoprecipitations were carried out essentially as described
[29,32,34]. Lysates prepared from HEK293 cells expressing BCR-Abl
or c-Abl along with GFP-TCPTP WT or mutant constructs were incu-
bated with equal amounts of test antibody or control mouse IgG. Im-
mune complexes were isolated using protein A/G plus agarose beads
and subjected toWestern blotting using Abl andGFP antibodies.Western
blotting was carried out using standard protocols as described earlier
[29,35]. About 50 μg of lysates were loaded to visualize the proteins by
Western blot with the ECL detection system (Perkin Elmer). Multiple an-
tigens were detected after deprobing.
2.6. Cell proliferation assay and STI571 sensitivity assay
Todetermine the cell proliferation rate, K562 cells (control) or stable
clones expressingGFP-TC48 or GFP-mTC48were seeded in triplicates in
96-well plates at a density of 5×103 cells perwell. Cell proliferationwas
quantiﬁed at 0 h, 24 h, 48 h and 72 h using an MTT assay. After the in-
dicated time, 20 μl of MTT (5 mg/ml, Sigma) was added to each well
and cultured for 4 h at 37 °C and 5% CO2. The liquid medium in the
wells was replaced with 200 μl dimethylsulphoxide (DMSO, Sigma),
and then the conversion of MTT into DMSO-soluble formazan by living
cells was quantiﬁed by measuring the absorbance at 590 nm using
SoftMax 190 ELISA reader (Spectramax190). Cell growth curves were
plotted with the OD value as ordinate and time as abscissa. Data repre-
sentmean±s.d. from at least three independent experimentswith cells
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ing GFP-TC48 or GFP-mTC48 were seeded as mentioned above and
treated with different concentrations of STI571. Cell proliferation was
quantiﬁed at 0 h and 48 h using an MTT assay as mentioned above.
Cell growth curves were plotted by normalizing all the OD values with
respect to those of the untreated cells. Data represent mean±s.d.
from at least ﬁve independent experiments.3. Results
3.1. TC48 interacts with BCR-Abl but not with c-Abl
In an attempt to identify novel cellular regulators of cellular and onco-
genic Abl kinases, we chose to examine whether TCPTP interacts with
BCR-Abl and c-Abl. Since substrate speciﬁcity of phosphatases is often de-
termined by their subcellular localization, we explored the possibility of
co-localization between TC48 and BCR-Abl or c-Abl. Cos-1 cells grown
on glass coverslips were transfected with BCR-Abl (or c-Abl) along with
GFP, GFP-TC48 or GFP-mutant-TC48 (GFP-mTC48) expression constructs
for 30 h, immunostained with Abl antibody and subjected to confocal
ﬂuorescence microscopy (Fig. 1a, b). TC48 normally shows a pattern of
localization consistent with its association with nuclear membranes,
Golgi and ER [21,22]. BCR-Abl shows a diffused cytoplasmic staining.
While BCR-Abl showed cytoplasmic and plasma membrane staining in
GFP or GFP-TC48 expressing cells, a signiﬁcant change in localization
was observed in mTC48 expressing cells, with prominent staining seen
in nuclear membrane and the Golgi region. In cells expressing mTC48,
BCR-Abl showed a localization pattern that matched the pattern of
mTC48. Cells expressing WT TC48 did not affect localization of BCR-Abl.
Quantitation of the co-efﬁcient of co-localization showed a good co-
localization of mTC48 with BCR-Abl but not with c-Abl (Fig. 1c). The nu-
clear isoform TC45 does not show any co-localizationwith BCR-Abl (data
not shown). Ectopically expressed c-Abl localizes to the cytoplasm with
some cells showing presence in the nucleus. c-Abl localization is not
altered upon co-expression of either TC48 or mTC48. No change in the
localization pattern of TC48 was observed upon co-expression with
BCR-Abl or c-Abl.
An interaction of BCR-Abl with TC48 was examined by co-
immunoprecipitation assays, using lysates from HEK293 cells ex-
pressing BCR-Abl and either GFP-TC48 or a substrate-trapping mu-
tant (GFP-mTC48). While very weak co-puriﬁcation of BCR-Abl was
observed with GFP-TC48, signiﬁcant co-precipitation was observed
with the substrate-trapping mutant TC48 indicating that BCR-Abl and
TC48 interact in vivo (Fig. 1d). Though TC45 isoform localizes to the nu-
cleus and does not match the localization of BCR-Abl, it was seen that
mTC45 did show co-precipitation with BCR-Abl from the cell lysates
(Supplementary Fig. 1a). The interaction between BCR-Abl and the
substrate-trap mutant of TC48 was partially disrupted upon treatment
with vanadate — a phosphotyrosine mimetic, further validating that
this interaction was dependent to some extent on the formation of the
substrate–enzyme complex (Fig. 1e).
Under conditions where BCR-Abl showed an interaction with TC48,
c-Abl showed no interaction (Fig. 1f). c-Abl is normally kept in a catalyt-
ically autoinhibited conformation in a cell. It gets activated by various
stimuli like oxidative stress leading to its autophosphorylation. To
check whether the lack of interaction between c-Abl and TC48 was be-
cause of a lack of Abl autophosphorylation in the lysates, c-Abl was ac-
tivated by H2O2 treatment before immunoprecipitation. No c-Abl
co-precipitation was observed in GFP immunoprecipitates from lysates
of cells expressing GFP-mTC48 along with c-Abl upon treatment with
H2O2 (Fig. 1f). We also examined the alternate possibility that BCR do-
main is responsible for interaction between mTC48 and BCR-Abl. It
was found that Myc-BCR fusion protein encompassing only the BCR
sequence (1–902 amino acids) of BCR-Abl could co-precipitate with
mTC48 (Fig. 1g). These ﬁndings indicated that TC48 interacts speciﬁcallywith BCR-Abl, but not with the cellular form as an interaction wasmedi-
ated through and dependent on the BCR domain.
3.2. TC48 dephosphorylates BCR-Abl and enhances its stability
Enhanced interaction of BCR-Abl with the substrate-trapping mu-
tant of TC48 compared to TC48, suggested that BCR-Abl could be a
potential substrate of TC48. Phospho-speciﬁc antibodies pY245 and
pY412, which speciﬁcally recognize phophorylated Abl at Y245 and
Y412 (corresponding to BCR-Abl Y1127 and Y1294) residues respec-
tively, and correlate with c-Abl (or BCR-Abl) activation status, were
used to determine the ability of TC48 to dephosphorylate BCR-Abl.
Cells transiently expressing BCR-Abl along with GFP, GFP-TC48 or
GFP-mTC48 were subjected to Western blotting with anti pY412,
pY245 or p-Tyr antibodies. Cells expressing BCR-Abl show autophos-
phorylation at both Y1127 and Y1294 residues, detected as signals on
polypeptides corresponding to BCR-Abl. The phospho-antibodies do
not detect any polypeptide in the untransfected cells. WT-TC48 expres-
sion led to the dephosphorylation of BCR-Abl at pY1127 and pY1294
residues whereas the mutant phosphatase failed to dephosphorylate
BCR-Abl at these residues (Fig. 2a). Coexpression ofWT-TC48 decreased
phosphorylation of BCR-Abl at Y1127 and Y1294 by over 80% as com-
pared to that obtained with GFP control or mTC48. To determine that
dephosphorylation correlates with expression levels of the phosphatase,
250 ng BCR-Ablwas transfectedwith 100 or 200 ng of theWT ormutant
phosphatase. As shown in Supplementary Fig. 2a, phospho-Abl levels de-
crease concomitantly with an increase in the amount of co-expressed
phosphatase. Reprobing the blots with Abl antibodies showed enhanced
BCR-Abl levels in lysates expressing theWT phosphatase where reduced
phosphorylationwas observed. Co-expressionwithmutant phosphatase
did not alter BCR-Abl-levels (Fig. 2a). Effect of TC48 andmTC48 on levels
of total BCR-Abl protein was examined under conditions of protein syn-
thesis inhibition using cycloheximide. As expected, BCR-Abl levels were
high in untreated cells expressing TC48 compared to cells expressing
mTC48 (Fig. 2b). During the course of cycloheximide treatment,
BCR-Abl levels remained stable in TC48 expressing cells and showed
a half life of 6.2 h compared to 1.75 h in mTC48 expressing cells
These results indicated that dephosphorylation by TC48 correlates
with the stabilization of BCR-Abl protein levels.
Dephosphorylation of BCR-Abl by TC48 was also examined in situ by
indirect immunoﬂuorescence. BCR-Abl expressing cells showed a consti-
tutive Abl activity as shown by positivity for phospho-Abl antibodies
pY412 (Fig. 2c) and pY245 (Supplementary Fig. 2b). BCR-Abl expressing
cells co-expressing WT GFP-TC48 did not show positivity for the
phospho-Abl antibodies indicating that TC48 dephosphorylated BCR-Abl
at these residues. In BCR-Abl expressing cells co-expressing the mutant
phosphatase (GFP-mTC48), BCR-Abl was not dephosphorylated and
showed co-localizationwithmutant TC48 as described earlier. Thesemol-
ecules were primarily in a phosphorylated state as indicated by their pos-
itivity for phospho-Abl antibodies and the co-localization of all the three
components i.e. GFP, Abl and phospho-Abl in these subcellular areas
(Fig. 2c). These ﬁndings indicated that BCR-Abl is indeed a substrate of
TC48 which targets the residues Y1127 and Y1294. Pre-treatment of
cells expressing the above constructs with sodium orthovanadate
(an inhibitor of PTPs) before lysis and immunoblotting, showed a de-
creased dephosphorylation of BCR-Abl by TC48 further validating
that the decrease in pAbl was a consequence of the phosphatase ac-
tivity (Fig. 2d). Co-expression of WT TC45 or mTC45 did not alter the
phosphorylation status of BCR-Abl at Y1127 and Y1294 as demonstrat-
ed in situ as well as in the cell lysates (Supplementary Fig. 1b, c, d).
3.3. Dephosphorylation of BCR-Abl by TC48 affects BCR-Abl activity
In order to characterize the consequence of BCR-Abl dephosphor-
ylation by TC48, the effect of this dephosphorylation on BCR-Abl me-
diated downstream signaling was studied. BCR-Abl is known to
Fig. 1. TC48 interactswith BCR-Abl but notwith c-Abl. (a, b) Colocalization of BCR-Abl and c-Ablwith TC48. Cos-1 cells transfectedwithGFP, GFP-TC48 or GFP-mutant TC48 (GFP-mTC48) along
with either BCR-Abl (a) or c-Abl (b) were stained for Abl and analyzed by confocal microscopy. Panels show single sections through the center of the nucleus. Bar, 10 μm. (c) Quantitation of
co-localization: co-efﬁcient of co-localization was determined using a Leica application suite advanced ﬂuorescence software and plotted from cells in multiple ﬁelds from at least three inde-
pendent experiments. (d) BCR-Abl co-precipitates with GFP-mTC48 from cell lysates. Lysates of HEK293 cells transfected with BCR-Abl along with GFP-TC48 or GFP-mTC48 were subjected to
immunoprecipitation using control mouse IgG or GFP antibodies. The immunoprecipitates were analyzed byWestern blotting with Abl and GFP antibodies. Whole cell lysates (WCL) used for
immunoprecipitation are also included to showexpression of theprotein. (e) Interaction ofmTC48withBCR-Abl is reduced by vanadate.HEK293 cells expressing BCR-Abl andGFP-mTC48were
left untreated (Utr) or treatedwith 50 μMvanadate (VO4) for 4 hprior to lysis and immunoprecipitation. Alongwith lysates (WCL), the immunoprecipitateswere subjected toWestern blotting
with the indicated antibodies. (f) c-Abl does not co-precipitatewithmTC48 from cell lysates. HEK-293 cells transfectedwith c-Abl alongwithGFP-TC48 orGFP-mTC48 (with orwithout addition
of 1 mMH2O2, an activator of c-Abl, for 30 min prior to lysis) were subjected to immunoprecipitation andWestern analysis as indicated in (d). Lysates expressing BCR-Abl with mTC48 were
subjected to immunoprecipitation under similar conditions to serve as a positive control. (g) The BCR domain of the BCR-Abl is sufﬁcient for interaction with mTC48. GFP and control IgG im-
munoprecipitates from cell lysates expressing Myc-BCR and GFP-mTC48 were subjected to Western blotting with Myc and GFP antibodies.
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Fig. 2. TC48 dephosphorylates and stabilizes BCRAbl. (a) Lysates of HEK293 cells expressing BCR-Abl along with either GFP, GFP-TC48 or GFP-mTC48 were subjected to Western
blotting with the indicated antibodies. (b)GFP-TC48 and GFP-mTC48 were co-expressed transiently with BCR-Abl for 24 h and treated with cycloheximide (CHX) for indicated
time, and subjected to Western analysis. (c) HEK293 cells grown on coverslips were transfected with BCR-Abl along with either GFP, (upper) GFP-TC48 (middle) or GFP-mTC48
(lower) and stained for indirect immunoﬂuorescence using Abl and p-Abl (pY412) antibodies and analyzed by confocal microscopy. Arrowheads (white) indicate BCR-Abl and TC48
co-expressing cells lacking p-Abl staining. Arrows (yellow) indicate BCR-Abl expressing cells lacking TC48 expression showing p-Abl staining. Bar, 10 μm. (d) Lysates of HEK293 cells ex-
pressing BCR-Abl along with GFP-TC48 or GFP-mTC48 (with or without 50 μM vanadate (VO4) treatment for 4 h prior to lysis) were subjected to Western blotting with the indicated
antibodies.
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is a target of Abl kinases and is not known to be a substrate of TC48.
The effect of TC48 mediated dephosphorylation on BCRAbl signaling
was examined by monitoring the endogenous phospho-Crk levels
with the aid of a phospho-speciﬁc antibody (pY221) that recognizes
CrkII phosphorylated at Y221. Cells transiently expressing BCR-Abl
along with GFP, GFP-TC48 or GFP-mTC48 were subjected to Western
blotting with anti pY221 and CrkII antibodies to assess the phosphor-
ylation status of endogenous CrkII. Expression of BCR-Abl resulted in
phosphorylation of Crk. Lysates of cells co-expressing WT GFP-TC48
along with BCR-Abl showed a reduction in p-Crk levels as compared to
those co-expressing control GFP or the mutant phosphatase (Fig. 3a).
This indicated that TC48 regulates BCR-Abl mediated phosphorylation
of Crk.
In situ, BCR-Abl expressing cells co-expressing GFP showed pY221
staining indicating phosphorylation of endogenous CrkII at Y221 by
BCR-Abl. But BCR-Abl expressing cells co-expressing WT GFP-TC48
did not show pY221 indicating inability of BCR-Abl to phosphorylate
CrkII (Fig. 4b). A direct dephosphorylation of pY221-CrkII by TC48 is
ruled out as CrkII is not a direct substrate of TC48 as shown by the
fact that TC48 does not dephosphorylate Crk Y221 when phosphorylat-
ed by other stimuli in cells that do not express BCR-Abl (Fig. 4a, Supple-
mentary Fig. 4). The reduced pCrk levels seen in BCR-Abl and TC48
expressing cells are therefore due to the effect of TC48 on BCR-Abl
and not due to the direct dephosphorylation of Crk. Cells
co-expressing BCR-Abl and GFP-mTC48 however showed pY221staining indicating inability of the mutant phosphatase to disrupt
BCR-Abl activity (Fig. 3b). This indicates that TC48 mediated dephos-
phorylation of BCR-Abl inhibits its activity towards phosphorylation of
cellular substrates.
3.4. TC48 does not dephosphorylate WT-c-Abl
Since TC48 was seen to dephosphorylate and regulate BCR-Abl, we
explored its ability to regulate WT c-Abl. Since WT c-Abl shows very
low activity, we activated c-Abl by treatment with H2O2. Cos-1 cells
transiently expressing c-Abl along with GFP, GFP-TC48 or GFP-m-TC48
were either kept untreated, or treated with H2O2, followed byWestern
blottingwith anti pY412, pY245 or p-Tyr antibodies. H2O2 treatment ac-
tivates c-Abl activity as indicated by the enhancement of phospho-Abl
levels. Unlike BCR-Abl, c-Abl activity is not affected by the presence of
WT or mutant TC48 indicating that TC48 does not dephosphorylate
c-Abl (Fig. 4a). Analyzing the Abl levels in the same blot indicated that
the phosphatase does not affect the stability of c-Abl unlike that of
BCR-Abl (Fig. 4a). This also correlates with the inability of TC48 to de-
phosphorylate c-Abl.
In our earlier work we have shown that, ectopic expression of c-Abl
shows a restricted activity only in the apoptotic cells with no activity in
the healthy cells when observed in situ [32]. Upon activation due to
H2O2 treatment c-Abl activity is seen in all cells. We have also shown
that treatment with phosphatase inhibitor, vanadate enhances c-Abl
activity. We wished to explore the status of c-Abl activity in the
Fig. 3. TC48 inhibits BCR-Abl activity towards Crk. (a) Lysates of HEK293 cells expressing BCR-Abl along with either GFP, GFP-TC48 or GFP-mTC48 were subjected to Western blot-
ting with p-Y221-Crk, Crk and indicated antibodies. (b) HEK293 cells transfected with BCR-Abl along with either GFP, GFP-TC48 or GFP-mTC48 were stained for indirect immuno-
ﬂuorescence using Abl and p-Crk (p-Y221) antibodies. Arrowheads (white) indicate BCR-Abl and TC48 co-expressing cells lacking p-Crk staining. Arrows (yellow) indicate BCR-Abl
expressing cells lacking TC48 expression showing p-Crk staining. Bar, 10 μm.
Fig. 4. c-Abl or its constitutively active mutants are not substrates of TC48. TC48 does not dephosphorylate c-Abl. (a) Lysates of HEK293 cells expressing c-Abl along with GFP,
GFP-TC48 or GFP-mTC48 (with or without 1 mM H2O2 treatment for 30 min prior to lysis to activate c-Abl) were subjected to Western blotting with the indicated antibodies.
(b) Cos-1 cells on coverslips were transfected with AblmPP and either GFP or GFP-TC48 and immunostained to detect p-Abl and Abl. (c,d,e) Constitutively active c-Abl mutants
are not substrates of TC48. Lysates of HEK293 cells expressing activated c-Abl constructs AblmPP (c), ΔXB (d), and ΔFABD (e) along with the indicated constructs were subjected
to Western blotting with the indicated antibodies.
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show suppression of Abl activity seen in apoptotic cells (Supplemen-
tary Fig. 3a). The enhancement of Abl activity upon H2O2 treatment
was also not affected by the presence of the phosphatase as cells co-
expressing c-Abl and GFP-TC48 and treated with H2O2 still showed uni-
form p-Abl staining throughout the cell. Cells co-expressing c-Abl and
GFP-mTC48 and treated with H2O2 did not have any effect on c-Abl
phosphorylation. Under similar conditions of H2O2 treatment, BCR-Abl
was dephosphorylated by TC48 indicating that overexpressed TC48
was not inhibited by the H2O2 treatment (Supplementary Fig. 3b).
This indicated that TC48 did not dephosphorylate c-Abl even in the
sub-cellular context.
CrkII is a known substrate and effector of c-Abl mediated signaling
[36,37]. To examine whether TC48 affects c-Abl mediated signaling,
we analyzed endogenous pY221 and CrkII levels under the above condi-
tions. An increase in p-Crk levels upon H2O2 treatment was observed
corresponding to an increase in c-Abl activity. The presence of the phos-
phatase did not affect p-Crk levels (Fig. 4a) in comparison to those in
the absence of TC48. In situ, c-Abl expressing cells co-expressing GFP
and treated with H2O2 showed pY221 staining indicating phosphoryla-
tion of CrkII at Y221 by c-Abl activated by H2O2. This phosphorylation
was unaffected by the presence of either theWTormutant phosphatase
(Supplementary Fig. 4a). These results suggest that TC48 does not reg-
ulate c-Abl activity towards Crk and also indicates that CrkII is not a di-
rect substrate of TC48.
c-Abl mutants like Abl mPP (with point mutations that disable SH3
binding), ΔXB (lacking the SH3 domain) and ΔFABD (lacking the
F-actin binding domain) are known to be constitutively active in con-
trast to the wild-type kinase. We found that like the wild-type c-Abl,
the constitutively activemutants of c-Abl are also not dephosphorylated
by TC48 indicating that the activation status of the kinase is not respon-
sible for c-Abl being a substrate of TC48 (Fig. 4b,c,d,e and Supplementa-
ry Fig. 3c). In addition, TC48 did not dephosphorylate endogenous
pCrkII when it was phosphorylated due to expression of Abl mPP
(Supplementary Fig. 4b).
3.5. TC48 inhibits proliferation and enhances sensitivity of K562 cells to
STI571
Dephosphorylation of BCR-Abl by TC48 prompted us to explore
the physiological relevance of this phenomenon. BCR-Abl is known
to regulate various properties of CML cells like cell proliferation and
response to drugs [3,38]. In this study we chose K562 cells (CML cell
line) positive for p210 BCR-Abl as a model system to study the effect of
TC48 on BCR-Abl functions. Stable clones expressing GFP, GFP-TC48 or
GFP-mTC48 in K562 cells were generated to carry out the study
(Fig. 5a). Cells expressing GFP-TC48 show reduced levels of phosphory-
lated BCR-Abl compared to control and GFP-mTC48 expressing cells
as detected by Western blotting and indirect immunoﬂourescence
(Fig. 5b,c). mTC48 expressing cells generally showed a higher level
of pAbl staining compared to control cells. A signiﬁcant increase in
the proliferation rate was seen in mTC48 expressing clones indicating
that dominant negative suppression of endogenous TC48 activity contrib-
utes to enhancing the proliferation rate. Clones expressing GFP-TC48
showed a slower rate of proliferation compared to control K562 cells or
clones expressing GFP-mTC48. This suggests that TC48 might regulate
cell proliferation mediated by BCR-Abl in K562 cells (Fig. 5d). TC48
expressing clones also showed altered sensitivity to STI571, a drug that
inhibits BCR-Abl kinase activity and used in the treatment of CML. The
difference was signiﬁcant at a low drug concentration (Fig. 5e). More
signiﬁcant difference in sensitivity to STI571 was seen in K562 cells
transiently expressing GFP-TC48 compared to those expressing GFP
(Supplementary Fig. 5b). GFP-TC48 expressing cells also show signiﬁ-
cantly reduced pAbl staining (Supplementary Fig. 5a). These results sug-
gest that altering intracellular TC48 levels could enable altered dose
response in hematopoetic malignancies due to BCR-Abl oncogene.4. Discussion
The transforming potential of the BCR-Abl oncogene is primarily due
to its constitutive kinase activity which is not subject to the normal re-
pressive mechanisms that control the cellular Abl kinase. Suppression
of kinase activity of BCR-Abl has thus far been the strategy to repress
its transforming ability in patients who develop BCR-Abl dependent ma-
lignancy. Inactivation of kinase activity by tyrosine phosphatases has re-
cently been explored as a strategy to repress transformation potential of
BCR-Abl [14,39]. Differences in the TCPTP expression has been shown to
contribute to the distinct biological characteristics of diffuse large B-cell
lymphomas [40]. A tumor suppressor role has been ascribed to TCPTP
with the ﬁnding of focal deletions being associated with T-ALL; but the
affected signaling events are not known [41,42]. In this study, we show
that the non-nuclear isoform of TCPTP, TC48 targets Y1127 and Y1294
residues of BCR-Abl (corresponding to Y245 and Y412 of c-Abl) and re-
presses its activity. Y245 and Y412 phosphorylations have additive ef-
fects on c-Abl and BCR-Abl activities. Our ﬁnding shows that TC48 can
dephosphorylate both the residues. The c-Abl tyrosine kinase localizes
to the nucleus as well as the cytoplasm and its activation correlates
with phosphorylation of Y245 and Y412. We provide the following evi-
dence to show that BCR-Abl and not c-Abl, is an interacting partner
and substrate of TC48: (1) better coimmunoprecipitation of a substrate
trappingmutant of TC48with BCR-Abl compared toWT TC48; (2) signif-
icant colocalization of BCR-AblwithmTC48; but not TC48; (3) absence of
colocalization or co-precipitationwith c-Abl; (4) BCR domain of BCR-Abl
is required for interaction with TC48; (5) inhibition of interaction be-
tween TC48 and Bcr-Abl in the presence of VO4; (6) coexpression of
TC48, but not its catalytic inactive mutant reduces Bcr-Abl phosphoryla-
tion at residues Y1127 and Y1294; (7) TC48 coexpression does not cause
dephosphorylation of c-Abl or its constitutively active variants; (8) TC48
inactivates BCR-Abl resulting in the decrease in phosphorylation of its
substrate CrkII; and (9) CrkII phosphorylation induced by activated
c-Abl is not altered upon TC48 expression.
Change in localization of BCR-Abl in cells coexpressing the mutant
enzyme is consistent with a high afﬁnity association between the two
molecules. Inhibition of interaction in cell lysates treated with vana-
date suggests that stable interaction is at least partially dependent
on catalytic domain of the phosphatase, indicative of direct interac-
tion between the kinase and phosphatase. We have recently shown
that TC48 interacts with C3G primarily through its non catalytic se-
quences, but depends on its catalytic domain to form a stable complex
[29]. Inability to dephosphorylate c-Abl was not due to the activation
status of Abl as c-Abl which was activated in response to oxidative
stress also did not show interaction and was not dephosphorylated
by TC48 indicating that dephosphorylation by TC48 was speciﬁc to
BCR-Abl. The interaction of TC48 with BCR-Abl was mediated through,
and dependent on BCR domain and therefore TC48 can interact only
with the oncogenic BCR-Abl fusion protein. This also explains why
TC48 dephosphorylates only BCR-Abl and not c-Abl or its constitutively
active variants.
Exclusive cytoplasmic localization contributes to the transforming
potential of the BCR-Abl oncoprotein. The nuclear isoform of TCPTP,
TC45 showed no dephosphorylation of BCR-Abl when tested in situ
or in the cell lysates. This was not due to a lack of interaction between
BCR-Abl and TC45, as BCR-Abl did interact with a substrate trapping
mutant of TC45 in the cell lysates. Subcellular partitioning plays an
important role in determining substrate speciﬁcity of intracellular ty-
rosine phosphatases. TC45 may be unable to act on BCR-Abl as intra-
cellularly, they are present in mutually exclusive compartments. The
ability of TC45 to interact with BCR-Abl from cell lysates is indicative
of their interaction after lysis. TCPTP levels are downregulated in STI
resistant cells and it has been shown that exogenous expression can
restore sensitivity [43]. The authors showed that resistant cells had
higher levels of phosphorylated STAT-5, a target of TCPTP. They ob-
served that TCPTP expression reduced pSTAT-5, but had no effect on
Fig. 5. TC48 negatively regulates K562 cell proliferation and enhances sensitivity to STI571. (a) Lysates of K562 cells (UT) or stable clones expressing GFP, GFP-TC48 or GFP-mTC48 were
subjected toWestern blotting with the indicated antibodies. (b) Dephosphorylation of BCR-Abl by TC48. Lysates fromK562 cells and clones expressing control and GFP-TC48were examined
for phosphorylated BCR-Abl by Western blotting. (c) Control K562 cells and those expressing GFP-TC48 or GFP-mTC48 were subjected to indirect immunoﬂourescence for expression of
pY245Abl. Bar, 10 μm. (d) Cell proliferation rate of K562 cells (control), stable clones expressing GFP-TC48, or GFP-mTC48 was determined using an MTT assay by measuring absorbance
at 590 nm. Cell growth curves were plotted with OD value as ordinate and time as abscissa. Data represent mean±s.d. from at least three independent experiments carried out in triplicate
wells. (e) Survival of K562 cells (control) or stable clones expressing GFP, GFP-TC48 or GFP-mTC48 treated with 0, 2.5 and 5 μM STI571 was quantiﬁed using MTT assay as indicated above.
Curves were plotted after normalizing with the OD value of the untreated samples. Data represent mean±s.d. from at least six independent experiments.
282 A. Mitra et al. / Biochimica et Biophysica Acta 1832 (2013) 275–284BCR-Abl or Jak2 phosphorylation. These authors used the TC45 iso-
form and showed that expression of TCPTP enhances sensitivity of
the CML cell line KT-1 to STI571 [28,43].
Phosphorylation of CrkII and CrkL by c-Abl and BCR-Abl is important
in the context of Abl mediated signaling [36,44,45]. While BCR-Abl ex-
pression shows a constitutive phosphorylation of endogenous CrkII on
Y221, activation of overexpressed c-Abl by H2O2 results in CrkII phos-
phorylation. We observed that CrkII phosphorylation mediated by
Bcr-Abl decreased upon TC48 expression, whereas no effect was seen
on levels of CrkII phosphorylation mediated by activated c-Abl. This re-
sult provided distinct evidence that TC48 inactivates Bcr-Abl effector
function towards CrkII, but not that of c-Abl. Effect on CrkII phosphory-
lation is directly through dephosphorylation and inactivation of Bcr-Abl.
It also indicated that TC48 does not directly dephosphorylate Y221 of
CrkII, providing further evidence that overexpressed TC48 acts on select
substrates in the intracellular context, even though CrkII is present in
the cytoplasmic compartment.
A variety of intracellular molecules that regulates c-Abl and
BCR-Abl activation has been identiﬁed. The PTPases PTP1B, SHPTP1,
PTPROt, SHPTP2 and STS-1 negatively regulate BCR-Abl and repress
its transforming properties. Except for results indicating that PTP1B
did not affect transformation induced by v-Abl, these studies have
not shown the effect of these phosphatases in suppressing c-Abl activity.
Reciprocal regulation has been shown between Bcr-Abl and some cellu-
lar PTPases. PTP1B, but not TCPTP levels increase in BCR-Abl expressing
cells [11]. PTP1B, but not TCPTP or PTP-PEST suppressed p210 BCR-Abl
induced activation of AP-1 reporter [46]. They showed that TCPTP did
not recognize BCR-Abl as a substrate and also did not affect BCR-Abl
induced signaling. It is possible that TC45 isoform was used in their
study. PTP1B expression (but not TCPTP) disrupted interaction of
Bcr-Abl with Grb2; suggesting that the phosphatase targeted Y177of BCR-Abl, the Grb2 binding site. The fact that mPTP1B also inhibited
BCR-Abl induced transformationwas indicative of disrupted association
between Grb2 and BCR-Abl. It was suggested that PTP1B may target
other sites on Bcr-Abl, but dephosphorylation of residues that coincide
with kinase activation was not demonstrated [11]. In Cos cells express-
ing BCR-Abl, expression of PTP1B showed reduced phosphotyrosine.
Under their experimental condition, expression of TCPTP had a very lit-
tle effect. mPTP1B and mPTPROt interact with and inhibit signaling
downstream of BCR-Abl; and have overall effects similar to the expres-
sion of wild type enzymes [11,14,46]. This has been explained to be due
to substrate trapping by the mutant phosphatases, thereby disabling
BCR-Abl from interacting with and phosphorylating downstream effec-
tors. In the case of TC48, though the mutant can trap BCR-Abl, its ex-
pression did not reduce Crk phosphorylation or repress proliferation
of K562 cells, as did the WT. In fact, mTC48 functioned as a dominant
negative, as shown earlier and resulted in enhanced cell proliferation.
The catalytically inactive mutant of the Escort phosphatase fusion
protein was ineffective in suppressing BCR-Abl mediated effects [39].
These differences may possibly be due to different modes of interaction
between BCR-Abl and the phosphatases. Our results therefore suggest
that TC48 alters BCR-Abl properties primarily dependent on its catalytic
activity by inactivating its kinase function through dephosphorylation
of key residues. Y1127 and Y1294 appear to be the primary sites of de-
phosphorylation, since examination of the overall tyrosine phosphory-
lation on BCR-Abl using pTyr antibodies, also showed a similar extent
of dephosphorylation. Of the other phosphatases known to interact
with BCR-Abl, only PTPROt has been shown to dephosphorylate a simi-
lar site [14].
Activated c-Abl is known to be downregulated by proteasome medi-
ated degradation ensuring optimal c-Abl activity in the cell [47]. BCR-Abl
was recently shown to be degraded primarily through the lysosomal
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in CML patients has been shown to be one of the reasons for Imatinib re-
sistance. Enhanced stability of the inactive BCR-Abl aids in growth inhibi-
tion and Imatinib sensitivity [38] because an intact, but enzymatically
inactive protein interferes with critical growth promoting signaling
pathways. Our results show that dephosphorylation of BCR-Abl and its
inactivation mediated by TC48 alters its stability, leading to enhanced
protein levels of the inactive molecule. Enhanced stability correlates
with dephosphorylation, as TC48 expression did not alter c-Abl levels.
The dual effects of TC48 on BCR-Abl, i.e. inactivation and enhancement
of stability can both contribute to the management of BCR-Abl positive
leukemia.
The signiﬁcance of TC48 as a cellular regulator of BCR-Abl activation
was conﬁrmed by results which showed a decreased proliferation of
TC48 expressing stable clones of K562 cells compared to control K562
cells or GFP expressing cells. Signiﬁcant increase was also seen in the
growth proﬁle of mTC48 expressing cells, where constitutive activity of
cellular TC48 is repressed due to a dominant negative effect shown by
mTC48. Our results therefore indicate that endogenous TC48 serves to
reduce BCR-Abl activity and regulate proliferation of K562 cells. Reduced
BCR-Abl activitywas earlier shown to correspondwith high sensitivity to
the BCR-Abl kinase inhibitor, STI571. Our results also show that enhanc-
ing TC48 levels in K562 cells signiﬁcantly increases sensitivity to low
doses of STI571. STI571 preferentially binds to the non-phosphorylated
conformation of Abl kinase domain [49]. Dephosphorylation of BCR-Abl
by TC48 may therefore enable better interaction with STI and enhance
sensitivity to the drug.
Presently, we have a good understanding of mechanisms involved
in the activation of oncogenic tyrosine kinases, but little is known
about cellular mechanisms involved in their inactivation. Considering
that c-Abl tyrosine kinase has speciﬁc physiologically important re-
pressive functions dependent on its kinase activation [1,6,50,51], it
is important that we aim at strategies that repress BCR-Abl and not
c-Abl functions. Dephosphorylation of BCR-Abl, leading to its inacti-
vation without affecting the activity of c-Abl is therefore a novel
mechanism of downregulating the transforming property of this onco-
gene. Activation of TCPTP can be achieved using small peptide agonists
[19]. This strategy can therefore be of potential use in suppressing ma-
lignancy due to BCR-Abl.
In summary, our results detail the identiﬁcation of an intracellular
tyrosine phosphatase, TC48 as a speciﬁc negative regulator of the onco-
genic BCR-Abl protein, having no effect on cellular Abl. BCR-Abl inter-
acts with and is a substrate of TC48, with Y1127 and Y1294 being the
primary target sites for dephosphorylation. Our data suggests that ele-
vated expression of TC48 or activation of the endogenous enzyme can
inhibit proliferation and enhance therapeutic response of CML cells to
STI571.
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